Structure Therapeutics reported that its oral obesity drug aleniglipron produced an 11.3 % mean weight loss—27.3 lbs—at 36 weeks in the core Phase 2b ACCESS study, with a 10.4 % adverse‑event‑related discontinuation rate across all active arms.
The 11.3 % weight loss is competitive with the best injectable GLP‑1 receptor agonists and demonstrates the potential of an oral small‑molecule alternative. In the exploratory ACCESS II study, a 240 mg dose achieved a 15.3 % weight loss—35.5 lbs—at the same time point, and no discontinuations were reported, underscoring the tolerability of the higher dose when initiated at a low 2.5 mg starting level.
The discontinuation rate of 10.4 % aligns with the class profile for GLP‑1 agents and is mitigated by a staggered dosing strategy that begins at 2.5 mg and escalates to 120 mg or 240 mg. This approach reduces gastrointestinal side effects and supports patient adherence, a key factor for long‑term obesity treatment success.
Structure Therapeutics’ cash position remains robust, with reserves sufficient to fund operations and the planned Phase 3 trial slated for mid‑2026. While the company continues to post net losses—a common pattern for clinical‑stage firms—the strong clinical data reinforce confidence in the company’s ability to secure additional financing and maintain its development pipeline.
CEO Raymond Stevens highlighted the significance of the results, stating that aleniglipron “delivers clinically meaningful, dose‑dependent weight loss with a safety profile appropriate for chronic use” and that the data support the drug’s potential as a scalable, combinable therapy for obesity.
Investor sentiment has been markedly positive, with the company’s shares reaching a new 52‑week high following the announcement. The enthusiasm reflects confidence in the drug’s oral convenience, competitive efficacy, and the company’s clear path to Phase 3.
Looking ahead, the Phase 3 trial will begin in mid‑2026, positioning aleniglipron to compete with established injectables such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. The company’s next‑generation structure‑based discovery platform and the demonstrated dose‑response relationship suggest a strong commercial opportunity in the projected $35.52 billion anti‑obesity market by 2032.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.